Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marco Ranzani

Showing results (11-20 of 24) with videos related to

Pageof 3
Sort By:
Nature Methods|January 15, 2013
Lentiviral vector-based insertional mutagenesis identifies genes associated with liver cancerMarco Ranzani, Daniela Cesana, Cynthia C Bartholomae, et al.
Blood|March 16, 2011
Lentiviral vector common integration sites in preclinical models and a clinical trial reflect a benign integration bias and not oncogenic selectionAlessandra Biffi, Cynthia C Bartolomae, Daniela Cesana, et al.
Genome Biology|April 19, 2015
CopywriteR: DNA copy number detection from off-target sequence dataThomas Kuilman, Arno Velds, Kristel Kemper, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|January 21, 2014
Uncovering and dissecting the genotoxicity of self-inactivating lentiviral vectors in vivoDaniela Cesana, Marco Ranzani, Monica Volpin, et al.
Science Translational Medicine|March 6, 2015
Liver-directed lentiviral gene therapy in a dog model of hemophilia BAlessio Cantore, Marco Ranzani, Cynthia C Bartholomae, et al.
Cell Chemical Biology|October 9, 2018
ALDH1 Bio-activates Nifuroxazide to Eradicate ALDH<sup>High</sup> Melanoma-Initiating CellsSana Sarvi, Richard Crispin, Yuting Lu, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|February 29, 2012
Preclinical safety and efficacy of human CD34(+) cells transduced with lentiviral vector for the treatment of Wiskott-Aldrich syndromeSamantha Scaramuzza, Luca Biasco, Anna Ripamonti, et al.
Nature Communications|February 27, 2021
Combinatorial CRISPR screen identifies fitness effects of gene paraloguesNicola A Thompson, Marco Ranzani, Louise van der Weyden, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 23, 2023
Small-Molecule Polθ Inhibitors Provide Safe and Effective Tumor Radiosensitization in Preclinical ModelsGonzalo Rodriguez-Berriguete, Marco Ranzani, Remko Prevo, et al.
Science Advances|June 12, 2026
<i>SHLD2</i> loss is a synthetic vulnerability to Polθ inhibition combined with radiotherapyGonzalo Rodriguez-Berriguete, Purusotha Thambiayah, Alessandro Cicconi, et al.
Pageof 3

Showing results (11-20 of 24) with videos related to

Sort By:
Pageof 3
Nature Methods|January 15, 2013
Lentiviral vector-based insertional mutagenesis identifies genes associated with liver cancerMarco Ranzani, Daniela Cesana, Cynthia C Bartholomae, et al.
Blood|March 16, 2011
Lentiviral vector common integration sites in preclinical models and a clinical trial reflect a benign integration bias and not oncogenic selectionAlessandra Biffi, Cynthia C Bartolomae, Daniela Cesana, et al.
Genome Biology|April 19, 2015
CopywriteR: DNA copy number detection from off-target sequence dataThomas Kuilman, Arno Velds, Kristel Kemper, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|January 21, 2014
Uncovering and dissecting the genotoxicity of self-inactivating lentiviral vectors in vivoDaniela Cesana, Marco Ranzani, Monica Volpin, et al.
Science Translational Medicine|March 6, 2015
Liver-directed lentiviral gene therapy in a dog model of hemophilia BAlessio Cantore, Marco Ranzani, Cynthia C Bartholomae, et al.
Cell Chemical Biology|October 9, 2018
ALDH1 Bio-activates Nifuroxazide to Eradicate ALDH<sup>High</sup> Melanoma-Initiating CellsSana Sarvi, Richard Crispin, Yuting Lu, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|February 29, 2012
Preclinical safety and efficacy of human CD34(+) cells transduced with lentiviral vector for the treatment of Wiskott-Aldrich syndromeSamantha Scaramuzza, Luca Biasco, Anna Ripamonti, et al.
Nature Communications|February 27, 2021
Combinatorial CRISPR screen identifies fitness effects of gene paraloguesNicola A Thompson, Marco Ranzani, Louise van der Weyden, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 23, 2023
Small-Molecule Polθ Inhibitors Provide Safe and Effective Tumor Radiosensitization in Preclinical ModelsGonzalo Rodriguez-Berriguete, Marco Ranzani, Remko Prevo, et al.
Science Advances|June 12, 2026
<i>SHLD2</i> loss is a synthetic vulnerability to Polθ inhibition combined with radiotherapyGonzalo Rodriguez-Berriguete, Purusotha Thambiayah, Alessandro Cicconi, et al.
Pageof 3